41 results
8-K
EX-99.1
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
of 2023.
Research and development (R&D) expenses for the first quarter of 2024 were $9.7 million, compared to $9.3 million for the same period … to the Ono partnership, partially offset by greater R&D operating expenses.
Cash, cash equivalents and short-term investments totaled $32.3 million
8-K
EX-99.1
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
of 2022.
Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period … in 2022. For the full year of 2023, R&D expenses were $37.0 million, compared with $37.5 million for the full year of 2022. The nominal year-over-year
8-K
EX-99.2
EQ
Equillium Inc
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
, Ltd. (Ono) and amortization of the upfront payment from Ono.
Research and development (R&D) expenses for the third quarter of 2023 were $9.0 million … estimated Australian R&D tax incentive benefit, a decrease in non-clinical research expenses, and a decrease in employee compensation and benefits.
General
8-K
EX-99.1
EQ
Equillium Inc
16 Oct 23
Regulation FD Disclosure
8:05am
upfront payment and full funding of itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab Closing payments … following delivery of: Equillium to continue conducting all itolizumab R&D topline data from the EQUALISE Ono to fund all R&D expenses from July 1, 2022
8-K
EX-99.1
EQ
Equillium Inc
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
Co, Ltd. (Ono) and amortization of the upfront payment from Ono.
Research and development (R&D) expenses for the second quarter of 2023 were $9.6 … estimated Australian R&D tax incentive benefit, a decrease in non-clinical research expenses, and a decrease in employee compensation and benefits related
8-K
EX-99.1
baaexmlt
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
425
5c6vdmj qkc3m3w2ht0
6 Dec 22
Business combination disclosure
4:53pm
425
flozm
6 Dec 22
Business combination disclosure
7:02am
8-K
EX-99.2
6iy50
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
8-K
EX-99.1
a1wgz t2ouxv5t
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am
425
2mt7k3 rwbdd
14 Nov 22
Business combination disclosure
4:20pm
8-K
EX-99.1
9zt 2ab5fr
14 Nov 22
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
4:10pm
424B3
6fim7y39s8r2p0nk6
10 Nov 22
Prospectus supplement
4:13pm
S-4/A
zyw5k0pxi87vw31h
9 Nov 22
Registration of securities issued in business combination transactions (amended)
4:31pm
S-4
e9ur58q q168b
26 Oct 22
Registration of securities issued in business combination transactions
9:59pm
425
djz7qmbwq myyx86uo
26 Sep 22
Business combination disclosure
5:29pm
8-K
EX-99.2
o55d 93lr
26 Sep 22
Report of Independent Registered Public Accounting Firm
5:27pm
425
yokuc9baia65xtfjye
6 Sep 22
Business combination disclosure
4:33pm
8-K
EX-99.2
wwemls xmbevjx
6 Sep 22
Equillium to Acquire Metacrine in All-Stock Transaction
4:29pm
8-K
EX-99.1
gos8adx 0bx9j
15 Aug 22
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
4:22pm